Acelrx Pharmaceuticals Inc Bruttó árrés

Mi az Acelrx Pharmaceuticals Inc Bruttó árrés?

A Bruttó árrés az Acelrx Pharmaceuticals Inc - -46.30%

Mi a Bruttó árrés meghatározása?

A bruttó árrés az árbevétel és az eladott áruk költségének különbsége, osztva bevételekkel, és százalékban kifejezve.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Mit csinál Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

bruttó árrés -hoz hasonló cégek Acelrx Pharmaceuticals Inc